Autoimmune problems of resistant schizophrenia: Lessons from rheumatology
V. G. Kaleda,
V. F. Mokhov,
D. V. Tikhonov,
I. S. Lebedeva,
T. N. Krasnova,
T. V. Beketova,
E. L. Nasonov https://doi.org/10.47360/1995-4484-2025-552-558
Abstract
The paper is devoted to modern ideas about the role of immune-inflammatory mechanisms in the development of resistant schizophrenia. The significance of autoimmune reactions is discussed. Promising targets of therapeutic strategies are considered.
About the Authors
V. G. Kaleda
Scientific Center for Mental Health
Russian Federation
Competing Interests:
Russian Federation
Vasily G. Kaleda
115522, Moscow, Kashirskoye Highway, 34
Competing Interests:
none
V. F. Mokhov
Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Vladimir F. Mokhov
119991, Moscow, Lomonosovsky avenue, 27/1
Competing Interests:
none
D. V. Tikhonov
Scientific Center for Mental Health
Russian Federation
Competing Interests:
Russian Federation
Denis V. Tikhonov
115522, Moscow, Kashirskoye Highway, 34
Competing Interests:
none
I. S. Lebedeva
Scientific Center for Mental Health
Russian Federation
Competing Interests:
Russian Federation
115522, Moscow, Kashirskoye Highway, 34
Competing Interests:
none
T. N. Krasnova
Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Tatiana N. Krasnova
119991, Moscow, Lomonosovsky avenue, 27/1
Competing Interests:
none
T. V. Beketova
V.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic University
Russian Federation
Competing Interests:
Russian Federation
Tatiana V. Beketova
115522, Moscow, Kashirskoye Highway, 34A; 121359, Moscow, Marshala Timoshenko str., 19, building 1A; 107023, Moscow, Bolshaya Semyonovskaya str., 38
Competing Interests:
none
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Evgeny L. Nasonov
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
none
References
1. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724. doi: 10.1038/ni.3731
2. Nasonov EL. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.). doi: 10.47360/1995-4484-2023-397-420
3. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395
4. Cabrera-Maqueda JM, Planagumà J, Guasp M, Dalmau J. Autoimmune neuropsychiatric disorders manifesting with psychosis. J Clin Invest. 2025;135(20):e196507. doi: 10.1172/JCI196507
5. Shiwaku H. Autoantibodies and inflammation in schizophrenia. Psychiatry Clin Neurosci. 2025;79(10):611-618. doi: 10.1111/pcn.13872
6. Klyushnik TP, Smulevich AB, Golimbet VYe, Zozulya SA, Voronova EI. The creation of clinical and biological concept of schizophrenia: Participation of chronic inflammation and genetic predisposition in the formation of psychopathological disorders. Psychiatry (Moscow). 2022;20(2):613 (In Russ.). doi: 10.30629/2618-6667-2022-20-2-6-13
7. Kaydan MA, Bravve LV. Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):43-50 (In Russ.). doi: 10.17116/jnevro202512502143
8. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77:69-77. doi: 10.1159/000112883
9. Tikhonov DV, Pomytkina AN, Kaleda VG. Modern aspects of resistance in schizophrenia. Mental Health. 2021;(12): 79-89 (In Russ.). doi: 10.25557/2074-014X.2021.12.79-89
10. Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatry. 2021;11(8):429-448. doi: 10.5498/wjp.v11.i8.429
11. Ying J, Chew QH, McIntyre RS, Sim K. Treatment-resistant schizophrenia, clozapine resistance, genetic associations, and implications for precision psychiatry: A scoping review. Genes (Basel). 2023;14(3):689. doi: 10.3390/genes14030689
12. Biso L, Carli M, Scarselli M, Longoni B. Overview of novel antipsychotic drugs: State of the art, new mechanisms, and clinical aspects of promising compounds. Biomedicines. 2025;13(1):85. doi: 10.3390/biomedicines13010085
13. Detanac M, Williams C, Dragovic M, Shymko G, John AP. Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates. Aust N Z J Psychiatry. 2024;58(12):1080-1089. doi: 10.1177/00048674241274314
14. Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257. doi: 10.1016/j.nbd.2018.08.016
15. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38. doi: 10.1111/j.0065-1591.2000.0ap25.x
16. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152(5):698-703. doi: 10.1176/ajp.152.5.698
17. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892-899. doi: 10.1093/schbul/sbu170
18. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: New developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. doi: 10.1016/S2215-0366(18)30050-6
19. Smulevich AB. The new psychopathological paradigm of schizophrenia and schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):715 (In Russ.). doi: 10.17116/jnevro20241240117
20. Kaleda V, Tikhonov D. Psychometric assessment of patients with treatment-resistant schizophrenia. Eur Psychiatry. 2024;67(Suppl 1):S749-S750. doi: 10.1192/j.eurpsy.2024.1560
21. Monteleone P, Cascino G, Rossi A, Rocca P, Bertolino A, Aguglia E, et al.; Italian Network for Research on Psychoses. Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study. Schizophr Res. 2022;248:279-286. doi: 10.1016/j.schres.2022.08.015
22. Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, et al. Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14(3):238. doi: 10.3390/ph14030238
23. Schmidt-Kastner R, Guloksuz S, Kietzmann T, van Os J, Rutten BPF. Mutation-intolerant genes and monogenic disease genes in 145 loci of schizophrenia (SCZ) GWAS are linked to the ischemia-hypoxia response. Schizophr Bull. 2019;45(Suppl 2):S342-S343. doi: 10.1093/schbul/sbz020.639
24. Dudina AN, Tikhonov DV, Vershinina OYu, Kaleda VG, Lebedeva IS. Structural MRI of the brain in treatment-resistant schizophrenia. Psychiatry (Moscow). 2024;22(1):15-25 (In Russ.). doi: 10.30629/2618-6667-2024-22-1-15-25
25. Itahashi T, Noda Y, Iwata Y, Tarumi R, Tsugawa S, Plitman E, et al. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. Neuroimage Clin. 2021;32:102852. doi: 10.1016/j.nicl.2021.102852
26. Huang H, Qin X, Xu R, Xiong Y, Hao K, Chen C, et al. Default mode network, disorganization, and treatment-resistant schizophrenia. Schizophr Bull. 2025 Mar 3:sbaf018. doi: 10.1093/schbul/sbaf018
27. Matrone M, Kotzalidis GD, Romano A, Bozzao A, Cuomo I, Valente F, et al. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between earlyand adult-onset patients. Prog Neuropsychopharmacol Biol Psychiatry. 2022;114:110493. doi: 10.1016/j.pnpbp.2021.110493
28. Chen W, Gou M, Wang L, Li N, Li W, Tong J, et al. Inflammatory disequilibrium and lateral ventricular enlargement in treatmentresistant schizophrenia. Eur Neuropsychopharmacol. 2023;72:18-29. doi: 10.1016/j.euroneuro.2023.03.014
29. Gou M, Li W, Tong J, Zhou Y, Xie T, Yu T, et al. Correlation of Immune-Inflammatory Response System (IRS)/Compensatory Immune-Regulatory Reflex System (CIRS) with white matter integrity in first-episode patients with schizophrenia. Mol Neurobiol. 2024;61(5):2754-2763. doi: 10.1007/s12035-023-03694-0
30. Saccaro LF, Crokaert J, Perroud N, Piguet C. Structural and functional MRI correlates of inflammation in bipolar disorder: A systematic review. J Affect Disord. 2023;325:83-92. doi: 10.1016/j.jad.2022.12.162
31. Nayak U, Manikkath J, Arora D, Mudgal J. Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: An update. Metab Brain Dis. 2025;40(2):119. doi: 10.1007/s11011-025-01548-3
32. Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: Theoretical underpinnings in schizophrenia. Front Pharmacol. 2012;3(1):195. doi: 10.3389/fphar.2012.00195
33. Liu J, Zhao W, Wang Y. Lights and shadows of clozapine on the immune system in schizophrenia: A narrative literature review. Metab Brain Dis. 2025;40(2):128. doi: 10.1007/s11011-02501558-1
34. Miller BJ, Goldsmith DR. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus (Am Psychiatr Publ). 2020;18(4):391-401. doi: 10.1176/appi.focus.20200015
35. Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75(4):300-6. doi: 10.1016/j.biopsych.2013.09.023
36. Jeppesen R, Benros ME. Autoimmune diseases and psychotic disorders. Front Psychiatry. 2019;10:131. doi: 10.3389/fpsyt.2019.00131
37. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am J Psychiatry. 2011;168(12):1303-1310. doi: 10.1176/appi.ajp.2011.11030516
38. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638-646. doi: 10.1111/j.1399-5618.2010.00853.x
39. Chen SJ, Chao YL, Chen CY, Chang CM, Wu EC, Wu CS, et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: Nationwide population-based study. Br J Psychiatry. 2012;200(5):374-380. doi: 10.1192/bjp.bp.111.092098
40. Sá ZC, Buinho A, Oliveira T, Soares FR, Rema JP, Novais F. Neuroinflamation treatment options in resistant schizophrenia – State of the art. Curr Treat Options Psych. 2025:12(26). doi: 10.1007/s40501-025-00356-x
41. Fontes H, Nzwalo H, Mendes S, Fernandes S, Ponte G, Pereira M. Central nervous system vasculitis presenting as acute psychotic disorder. Eur Psychiatry. 2011;26(S2):745-745. doi: 10.1016/S0924-9338(11)72450-6
42. Beketova TV, Konovalov RN. Susac’s syndrome (retinocochleocerebral vasculopathy). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(2): 249-252 (In Russ.). doi: 10.14412/1995-4484-2018-249-252
43. Gasparinho R, Fernandes N, Martins M, Santos N, Ferreira LP, Alho A. Psychosis as the first manifestation of granulomatosis with polyangiitis – A case report. Psychiatr Danub. 2022;34(2):315-317. doi: 10.24869/psyd.2022.315
44. Duarte EV, Suárez GP, Hernández SV, Beltrán JC. Psicosis y alteraciones en la sensopercepción como manifestaciones atípicas de la poliangitis microscópica. Revista Colombiana de Reumatología. 2020;27(2):135-140. doi: 10.1016/j.rcreue.2019.04.008
45. Patel P, Steinschneider M, Boneparth A, Lantos G. Neuro-Behçet disease presenting with acute psychosis in an adolescent. J Child Neurol. 2014;29(9):NP86-NP91. doi: 10.1177/0883073813504137
46. Lin CE. One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms. Neuropsychiatr Dis Treat. 2016;12:661-663. doi: 10.2147/NDT.S97753
47. Hajjaj I, Adali I, Idrissi Ouali M, Kissani N. Un accès psychotique aigu révélateur d’un neurolupus avec images atypiques à l’IRM encéphalique [An acute psychotic episode revealing neuropsychiatric lupus with atypical brain MRI]. Encephale. 2012;38(6):519-523 (In French). doi: 10.1016/j.encep.2012.04.004
48. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19(1):47-52.
49. Pizova NV. Neuropsychiatric disorders in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8):76-83 (In Russ.).
50. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann N Y Acad Sci. 1987;496:676-685. doi: 10.1111/j.1749-6632.1987.tb35829.x
51. Tanaka S, Matsunaga H, Kimura M, Tatsumi Ki, Hidaka Y, Takano T, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003;141(12):155-164. doi: 10.1016/s0165-5728(03)00252-2
52. Laske C, Zank M, Klein R, Stransky E, Batra A, Buchkremer G, Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res. 2008;158(1):83-86. doi: 10.1016/j.psychres.2006.04.023
53. Schott K, Schaefer JE, Richartz E, Batra A, Eusterschulte B, Klein R, et al. Autoantibodies to serotonin in serum of patients with psychiatric disorders. Psychiatry Res. 2003;121(1):51-57. doi: 10.1016/s0165-1781(03)00137-9
54. Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150(1):245-251. doi: 10.1016/j.schres.2013.07.029
55. van Mierlo HC, de Witte L, Derksen RH, Otten HG; GROUP investigators. The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: Results from a large cohort study. NPJ Schizophr. 2015;1:15013. doi: 10.1038/npjschz.2015.13
56. Alarcón-Segovia D, Fishbein E, Cetina JA, Raya RJ, Barrera E. Antigenic specificity of chlorpromazine-induced antinuclear antibodies. Clin Exp Immunol. 1973;15(4):543-548.
57. Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry. 1967;16(1):1-9. doi: 10.1001/archpsyc.1967.01730190003001
58. Heath RG, Krupp IM. Catatonia induced in monkeys by antibrain antibody. Am J Psychiatry. 1967;123(12):1499-1504. doi: 10.1176/ajp.123.12.1499
59. Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev. 2011;7(3):189-193. doi: 10.2174/1573400117971831849
60. Yucel Y, Sidow NO, Yilmaz A. Approach and overview of autoimmune encephalitis: A review. Medicine (Baltimore). 2025;104(21):e42472. doi: 10.1097/MD.0000000000042472
61. Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839-887. doi: 10.1152/physrev.00010.2016
62. Ramirez-Bermudez J, Espinola-Nadurille M, Restrepo-Martinez M, Martínez-Ángeles V, Martínez-Carrillo F, Cascante L, et al. Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy. Schizophr Res. 2025;281:10-19. doi: 10.1016/j.schres.2025.04.024
63. Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: A systematic review and meta-analysis. Psychol Med. 2014;44(12):2475-2487. doi: 10.1017/S003329171300295X
64. Shiwaku H, Katayama S, Kondo K, Nakano Y, Tanaka H, Yoshioka Y, et al. Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice. Cell Rep Med. 2022;3(4):100597. doi: 10.1016/j.xcrm.2022.100597
65. Shiwaku H, Katayama S, Gao M, Kondo K, Nakano Y, Motokawa Y, et al. Analyzing schizophrenia-related phenotypes in mice caused by autoantibodies against NRXN1α in schizophrenia. Brain Behav Immun. 2023;111:32-45. doi: 10.1016/j.bbi.2023.03.028
66. Klyushnik TP, Zozulya SA. Immunology of schizophrenia: A modern view on inflammatory hypotheses of the disease. Psychiatry (Moscow). 2024;22(4):14-25 (In Russ.). doi: 10.30629/2618-6667-2024-22-4-14-25
67. Patlola SR, Holleran L, Dauvermann MR, Rokita K, Laighneach A, Hallahan B, et al. Investigating the relationship between Toll-like receptor activity, low-grade inflammation and cognitive deficits in schizophrenia patients – A mediation analysis. Brain Behav Immun. 2025;128:529-539. doi: 10.1016/j.bbi.2025.04.024
68. Zhu Y, Webster MJ, Walker AK, Massa P, Middleton FA, Weickert CS. Increased prefrontal cortical cells positive for macrophage/ microglial marker CD163 along blood vessels characterizes a neuropathology of neuroinflammatory schizophrenia. Brain Behav Immun. 2023;111:46-60. doi: 10.1016/j.bbi.2023.03.018
69. Zhilyaeva TV, Rukavishnikov GV, Manakova EA, Mazo GE. Serum interleukin-6 in schizophrenia: Associations with clinical and sociodemographic characteristics. Consort Psychiatr. 2023;4(4):5-16. doi: 10.17816/CP11067
70. Shnayder NA, Khasanova AK, Strelnik AI, Al-Zamil M, Otmakhov AP, Neznanov NG, et al. Cytokine imbalance as a biomarker of treatment-resistant schizophrenia. Int J Mol Sci. 2022;23(19):11324. doi: 10.3390/ijms231911324
71. Leboyer M, Godin O, Terro E, Boukouaci W, Lu CL, Andre M, et al.; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups. Immune signatures of treatmentresistant schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) study. Schizophr Bull Open. 2021;2(1):sgab012. doi: 10.1093/schizbullopen/sgab012
72. Szota AM, Ćwiklińska-Jurkowska M, Radajewska I, Lis K, Grudzka P, Dróżdż W. Effect of electroconvulsive therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and soluble IL-2 receptor in treatment-resistant schizophrenia (TRS) patients – A preliminary study. J Clin Med. 2025;14(9):3170. doi: 10.3390/jcm14093170
73. He J, Li J, Wei Y, He Z, Liu J, Yuan N, et al. Multiple serum antiglutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia. BMC Psychiatry. 2024;24(1):248. doi: 10.1186/s12888-024-05689-0
74. Tong J, Zhou Y, Huang J, Zhang P, Fan F, Chen S, et al. N-methyl-D-aspartate receptor antibody and white matter deficits in schizophrenia treatment-resistance. Schizophr Bull. 2021;47(5):1463-1472. doi: 10.1093/schbul/sbab003
75. Hoprekstad GE, Johnsen E, Bartz-Johannessen C, Bjarke JK, Drosos P, Fasmer OB, et al. Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study. Brain Behav Immun Health. 2025;48:101047. doi: 10.1016/j.bbih.2025.101047
76. Girgis RR, Ciarleglio A, Choo T, Haynes G, Bathon JM, Cremers S, et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology. 2018;43(6):1317-1323. doi: 10.1038/npp.2017.258
77. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. doi: 10.1001/2013.jamapsychiatry.4
78. Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial. Brain Behav Immun. 2024;115:191-200. doi: 10.1016/j.bbi.2023.10.012
79. Bejerot S, Sigra Stein S, Welin E, Eklund D, Hylén U, Humble MB. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two openlabel pilot studies on treatment-resistant patients. J Psychiatr Res. 2023;158:319-329. doi: 10.1016/j.jpsychires.2022.12.003
80. Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40
81. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470-475. doi: 10.1136/ard.2006.057885
82. Rodziewicz M, Dyball S, David T, Sutton E, Parker B, Bruce IN. The effectiveness of rituximab in the real-world treatment of neuropsychiatric SLE: Results from the British Iles Lupus Assessment Group Biologics Register (BILAG-BR). Ann Rheum Dis. 2024;83:137-138. doi: 10.1136/annrheumdis-2024-eular.4840
83. Angeletti A, Baraldi O, Chiocchini AL, Comai G, Cravedi P, La Manna G. Rituximab as first-line therapy in severe lupus erythematosus with neuropsychiatric and renal involvement: A casereport and review of the literature. J Clin Case Rep. 2017;7(10):1033. doi: 10.4172/2165-7920.10001033
84. Wang H, Zhao L, Yang S, Ding H, Wu W, Yu L, et al. Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus. Front Immunol. 2025;16:1599473. doi: 10.3389/fimmu.2025.1599473
85. Griffiths K, Mellado MR, Chung R, Lally J, McQueen G, Sendt KV, et al. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain Behav Immun. 2024;115:223-228. doi: 10.1016/j.bbi.2023.10.001
86. Ota VK, Spindola LM, Stavrum AK, Costa GO, Bugiga AVG, Noto MN, et al. Longitudinal DNA methylation and cell-type proportions alterations in risperidone treatment response in firstepisode psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;139:111402. doi: 10.1016/j.pnpbp.2025.111402
87. Boukouaci W, Lajnef M, Wu CL, Bouassida J, Saitoh K, Sugunasabesan S, et al. B cell-activating factor (BAFF): A promising transnosographic biomarker of inflammation and autoimmunity in bipolar disorder and schizophrenia. Brain Behav Immun. 2024;121:178-188. doi: 10.1016/j.bbi.2024.07.025
88. Li L, Shen S, Shao S, Dang E, Wang G, Fang H, et al. The role of B cell-activating factor system in autoimmune diseases: Mechanisms, disease implications, and therapeutic advances. Front Immunol. 2025;16:1538555. doi: 10.3389/fimmu.2025.1538555
89. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383
90. Nasonov EL, Rumyantsev AG, Samsonov MYu. Pharmacotherapy of autoimmune rheumatic diseases – From monoclonal antibodies to CAR T cells: 20 years later. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(3):262-279 (In Russ.). doi: 10.47360/1995-4484-2024-262-279
Review
For citations:
Kaleda V.G., Mokhov V.F., Tikhonov D.V., Lebedeva I.S., Krasnova T.N., Beketova T.V., Nasonov E.L. Autoimmune problems of resistant schizophrenia: Lessons from rheumatology. Rheumatology Science and Practice. 2025;63(6):552-558. (In Russ.) https://doi.org/10.47360/1995-4484-2025-552-558
Views:
22
Email this article 